EarningsQ4 2026 Earnings Report
DE:CSJA Q4 2026 EPS Results
Actual EPS-€1.35
Consensus EPS―
Beat/Miss―
One Year Ago EPS€0.44
DE:CSJA Q4 2026 Revenue Results
Actual Revenue€6.42B
Expected Revenue―
Beat/Miss―
YoY Revenue Growth+6.19%
Earnings Announcement Details
QuarterQ4 2026
Date08/17/2026
TimeAfter Close
Conference CallMonday, August 17, 2026
DE:CSJA Upcoming Earnings
CSL's next earnings date is estimated for February 9, 2027, based on past reporting schedules.
Q4 2026 Earnings Call Audio
DE:CSJA Q4 2026 Earnings Call
0:00 / 0:00
Q4 2026 Earnings Slide Deck
Q4 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed picture: operational and commercial turnaround actions are beginning to show early, tangible benefits (strong cash flow, successful transformation savings, Seqirus market outperformance, Ig momentum and promising product launches), but these positives are offset by very large impairments, significant and structural headwinds in Vifor (expected ~25% revenue decline in FY'27), continued albumin pricing pressure in China and an FY'26 statutory loss driven by noncash charges. Management’s FY'27 underlying guidance (NPAT +~5% cc; Behring growth) and capital returns indicate confidence in a return to profitable growth, yet the scale of recent impairments and the outlook for Vifor mean near-term headwinds remain material.Company Guidance
Strong cash generation and capital returns
Operating cash flow of $3.5 billion supported completion of an AUD 1.0 billion share buyback, a new AUD 1.1 billion buyback authorization for FY'27, and maintenance of the full-year dividend at $2.92 per share (U.S. dollar basis); net debt/EBITDA finished at 1.8x within target range.
Transformation program delivering savings ahead of plan
Transformation delivered $176 million of FY'26 savings (ahead of a $100 million target). Incremental savings of ~ $220 million expected in FY'27 taking annualized savings to ~ $400 million and up to $550 million in FY'28; some of the savings are being selectively reinvested in commercial and R&D initiatives.
Seqirus outperforms seasonal influenza market
Seqirus was the only global vaccine company to grow seasonal influenza revenue year‑on‑year: seasonal influenza revenue +4%; adjuvanted portfolio +5%; cell culture revenue +5%. Seqirus revenue was $2.0 billion (down 8% overall due to nonrecurrence of FY'25 avian flu sales) but showed product and share gains across key markets.
Improving Ig commercial momentum in CSL Behring
CSL Behring revenue $11.4 billion (down 1% cc). Underlying Ig demand described as robust: full-year Ig broadly flat, but second-half Ig revenue +7% on prior comparable period and +4% vs the immediate preceding half, indicating early benefits from U.S. and China commercial investments and maintained patient share in HIZENTRA.
Strong performance from newer products
ANDEMBRY launch ahead of expectations and now available in 19 markets; HEMGENIX revenue grew 25% year‑on‑year; Phase III for VarmX candidate commenced and other targeted licensing (e.g., clazakizumab to Lilly) to focus resources.
Operational actions to improve plasma productivity and yields
Plasma network optimization: underperforming centers closed without reducing overall collections; transition of a portion of U.S. centers to Haemonetics platform; yield improvement initiatives underway and construction commenced for Kankakee IG facility (Horizon 2). Management is pursuing digital donor engagement and AI use cases to improve productivity and lower unit supply costs.
Cost discipline while maintaining strategic investment
R&D expense down 13% to $1.2 billion and General & Admin down 13% in FY'26, while continuing to invest in priority programs (e.g., ~$50 million invested in VarmX and $30 million reinvested in commercial initiatives in FY'26).
FY'27 underlying earnings and revenue guidance
Guidance calls for group revenue broadly in line with FY'26 on a constant currency basis and underlying NPAT growth of ~5% (cc). Behring expected to deliver mid-single-digit revenue growth and Ig to grow mid- to high-single-digit in line with market; Seqirus expected to grow low single-digit.
DE:CSJA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed